论文部分内容阅读
文献尚未明确对低度恶性组织细胞型非何杰金淋巴瘤诱导缓解后巩固强化抑或是维持化疗有益。本文报告162例,男85例,女77例,中数年龄53岁,ⅢA期52例,ⅢB6例,ⅣA60例,ⅣB 44例,均经活检证实。诱导缓解治疗使用CVP方案(CVR 2mg第1日,环磷酰胺400mg/m~2/日口服,强的松龙40mg/日),5日,3周为一疗程,重复应用6-10疗程至完全缓解(CR),接着对以前肿大淋巴结区域给予放疗,以防复发。然后随机分成两组,一组仅随访观察,不给任何治疗;一组口服苯丁酸氮芥10mg/日×14天,休息2周,维持治疗重复应用2年。本组56%患者取得CR(其中苯丁酸氮芥组54%,随访观察组57%),37%取得PR,中数生存期是64个月(随访日期自
The literature has not yet clearly demonstrated the benefit of postconsolidation-enhanced or enhanced chemotherapy for the induction of remission in patients with low-grade malignant histiocytosis of non-Hodgkin’s lymphoma. This article reports 162 cases, 85 males and 77 females, median age 53 years, 52 cases of IIIA, 6 cases of IIIB, 60 cases of IVA, 44 cases of IVB, all confirmed by biopsy. Induced remission therapy using CVP regimen (CVR 2 mg on day 1, cyclophosphamide 400 mg/m 2/day orally, prednisolone 40 mg/day), 5 days, 3 weeks as a course of treatment, repeated application of 6-10 courses to Complete remission (CR), followed by radiotherapy to previously enlarged lymph nodes to prevent recurrence. They were then randomly divided into two groups. One group was only followed up for observation and no treatment was given. One group was treated with chlorambucil 10 mg/day for 14 days and rested for 2 weeks. Maintenance therapy was repeated for 2 years. 56% of patients in this group received CR (54% in the chlorambucil group and 57% in the follow-up group), 37% achieved PR, and median survival was 64 months.